Strategic market access – a novel approach
A client with highly specialised therapies for serious & life-threatening diseases engaged HTAnalysts.
Negotiate a complex risk-share agreement that required:
Building a mutually acceptable pricing mechanism. Liaising with clients stakeholders (local affiliate, global HEOR & pricing, medical and corporate teams), and the Government Stakeholders, including the DoH, PBAC and the Minister. Facilitating and reaching agreement with all stakeholders.
Application to the PBAC completed by HTAnalysts.
Argument strengthened with respect to survival gain, dose adjustments and utility benefits.
Additional local evidence
Obtained (ultimately used internationally). Innovative performance-based pricing strategy developed replacing ‘usual practice’ of initiation and continuation rules.
Internal financial modelling
Developed by HTAnalysts taking into account various performance outcomes and pricing scenarios.
HTAnalysts negotiated final complex risk-sharing arrangement with appropriate post-listing evidence collection.
Successful reimbursement with ongoing access for all eligible patients, achieved in faster time than comparable highly-specialised products.